IRIS
DI RAIMONDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.138
AS - Asia 10.809
EU - Europa 10.136
SA - Sud America 2.361
AF - Africa 1.021
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 20
Totale 50.514
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.085
SG - Singapore 5.591
CN - Cina 3.485
IE - Irlanda 2.647
IT - Italia 2.579
UA - Ucraina 2.395
BR - Brasile 2.020
CA - Canada 903
RU - Federazione Russa 710
CI - Costa d'Avorio 679
VN - Vietnam 557
SE - Svezia 331
DE - Germania 313
GB - Regno Unito 303
IN - India 284
KR - Corea 220
SN - Senegal 139
AR - Argentina 134
FI - Finlandia 117
FR - Francia 112
NL - Olanda 106
PL - Polonia 100
MX - Messico 99
CH - Svizzera 88
BD - Bangladesh 82
JP - Giappone 82
UZ - Uzbekistan 82
ZA - Sudafrica 74
EC - Ecuador 65
AT - Austria 61
TR - Turchia 58
IQ - Iraq 52
ES - Italia 51
CZ - Repubblica Ceca 50
HK - Hong Kong 48
BE - Belgio 47
GR - Grecia 44
ID - Indonesia 36
LB - Libano 36
CO - Colombia 35
MA - Marocco 34
VE - Venezuela 27
IR - Iran 26
PK - Pakistan 26
AU - Australia 20
PY - Paraguay 20
CL - Cile 19
IL - Israele 19
BJ - Benin 18
EU - Europa 18
SA - Arabia Saudita 17
PE - Perù 16
EG - Egitto 15
JO - Giordania 15
KE - Kenya 15
TN - Tunisia 14
AE - Emirati Arabi Uniti 13
BG - Bulgaria 13
BO - Bolivia 13
LT - Lituania 13
DO - Repubblica Dominicana 12
NG - Nigeria 12
RS - Serbia 12
AZ - Azerbaigian 11
DZ - Algeria 10
KZ - Kazakistan 10
NO - Norvegia 9
UY - Uruguay 9
RO - Romania 8
CR - Costa Rica 7
MY - Malesia 7
NZ - Nuova Zelanda 7
PS - Palestinian Territory 7
JM - Giamaica 6
KW - Kuwait 6
NP - Nepal 6
TH - Thailandia 6
AL - Albania 5
BH - Bahrain 5
OM - Oman 5
PH - Filippine 5
SI - Slovenia 5
TT - Trinidad e Tobago 5
BB - Barbados 4
PA - Panama 4
HN - Honduras 3
LU - Lussemburgo 3
PT - Portogallo 3
AM - Armenia 2
AO - Angola 2
BF - Burkina Faso 2
DK - Danimarca 2
EE - Estonia 2
GD - Grenada 2
HU - Ungheria 2
KG - Kirghizistan 2
LK - Sri Lanka 2
NI - Nicaragua 2
SR - Suriname 2
SV - El Salvador 2
Totale 50.487
Salva come PNG Salva come JPEG
Città #
Dallas 5.114
Santa Clara 2.900
Singapore 2.725
Jacksonville 2.636
Dublin 2.628
Chandler 2.134
Boardman 1.117
Chicago 954
Catania 899
Ashburn 832
Nanjing 751
Cambridge 720
Andover 716
Lawrence 715
Abidjan 677
Toronto 650
Houston 508
Hefei 501
Des Moines 423
Beijing 394
San Mateo 386
Los Angeles 369
Nanchang 262
Wilmington 261
Civitanova Marche 229
Seoul 220
Saint Petersburg 182
Shenyang 180
Hebei 176
São Paulo 174
Ho Chi Minh City 170
Ottawa 148
Jiaxing 147
Dakar 138
Changsha 134
Florence 133
New York 130
Buffalo 118
Tianjin 110
Hanoi 105
Rome 98
Grafing 96
Council Bluffs 94
Kochi 92
Dong Ket 87
Milan 83
Munich 71
Palermo 71
Brooklyn 70
Tokyo 70
Seattle 66
Moscow 65
Warsaw 62
Rio de Janeiro 58
Washington 58
Montreal 54
Stockholm 51
The Dalles 51
Boston 50
Johannesburg 50
San Francisco 49
Belo Horizonte 47
Columbus 46
Hangzhou 45
Hong Kong 45
Phoenix 44
Redondo Beach 44
Brussels 42
Turku 42
Chennai 40
Den Haag 39
Poplar 39
Helsinki 38
Norwalk 37
Lappeenranta 36
Denver 35
Kunming 35
Atlanta 32
Falls Church 32
Pune 32
Tashkent 32
Mexico City 31
Mumbai 31
London 30
Jinan 29
Porto Alegre 29
Bremen 28
Orem 28
Brasília 27
Amsterdam 26
Curitiba 26
Ankara 25
Guangzhou 25
Campinas 24
Bari 22
Brno 22
Guayaquil 22
Messina 22
Quito 22
Ann Arbor 20
Totale 34.483
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 246
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 246
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 185
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 178
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 178
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 171
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 159
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 152
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 151
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 147
Il Rasario. Semeiotica medica 142
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib 138
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 138
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 133
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 133
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 131
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 130
A PHASE III STUDY OF ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-DOSE WARFARIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED UP-FRONT WITH THALIDOMIDE BASED-REGIMENS 129
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 129
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 128
Hedgehog signaling pathways in multiple myeloma 123
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 123
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 122
A snapshot of asparaginase-induced liver insufficiency. 122
Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification 121
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 121
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 121
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 120
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 119
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 118
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 118
A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS 117
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 117
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 117
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 116
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 115
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol 115
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 115
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia 114
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 113
Acute pre-hepatic portal thrombosis: diagnosis and therapy 112
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD 112
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 112
A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents 112
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 111
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 111
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 111
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 110
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 110
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 110
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 109
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 109
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 109
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 108
A case of high-risk AML in a patient with advanced systemic mastocytosis 107
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 107
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 107
A NEW CYTOGENETIC ABNORMALITY, T(1;4) (P22;P16) IN AML M4 PATIENT AFTER CHEMOTHERAPY TREATMENT 107
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 107
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 105
A GLOBAL PROGRESSION RISK SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: THE NEVER-ENDING STORY 105
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 105
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 105
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 104
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over 104
Terapia del mieloma multiplo 104
A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis 104
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma 104
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 104
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 103
Bone turnover markers in patients with type 1 Gaucher disease 103
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 103
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 102
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 102
A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients 102
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 101
Analysis of metabolic parameters coming from basal and interim PET in hodgkin lymphoma 101
Eventi avversi e trigger C12: Stroke in ospedale 101
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 100
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines 100
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 100
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia 100
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 99
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 97
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 96
CIRCULATING ARGINASE-1 IN SERUM IS A NOVEL BIO-MARKERIN HODGKIN LYMPHOMA 96
Acute myeloid leukemia in elderly patients. 95
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 95
BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia 94
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 94
Angiogenesis in acute myeloid leukemia 94
CD200 EXPRESSION ON MYELOMA CELLS AND ANTITUMOR IMMUNITY 94
A Multicentric clinical trial of salvage therapy with thalidomide for patients with advanced relapsed and refractory multiple myeloma 94
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 94
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 94
Cementoplasty in the management of painful extraspinal bone metastases: our experience 93
The Heme Oxygenase System in Hematological Malignancies 93
A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones? 93
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 92
Lymphoma of the cecum: a case report 92
Totale 11.653
Salva come PNG Salva come JPEG
Categoria #
all - tutte 196.497
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 196.497
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.881 0 0 0 0 1.175 67 540 13 470 8 430 178
2021/20225.171 637 763 22 43 872 42 762 175 524 28 122 1.181
2022/20237.429 743 273 104 503 714 1.384 24 1.266 1.976 58 274 110
2023/20243.154 209 432 133 251 142 514 68 206 15 86 676 422
2024/202512.800 99 2.090 837 448 2.795 1.044 380 521 1.091 1.399 960 1.136
2025/202612.654 1.673 1.754 5.013 1.882 2.332 0 0 0 0 0 0 0
Totale 51.570